Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1101-1120 of 3,900 trials

Ulcerative Colitis: Novel Rifamycin Enema

We are testing a new rifamycin solution for patients with mild to moderate left-sided ulcerative colitis. The study aims to see if it helps improve symptoms and induce remission compared to a placebo.

Left-Sided Ulcerative Colitis3-6 monthsEfficacy phase (II)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Stroke Treatment: Intra-Arterial Thrombolysis Study

We are studying whether adding a specific clot-dissolving treatment helps improve recovery in patients with acute strokes who have already had successful blood flow restoration. This trial will also evaluate safety and costs associated with this treatment.

Ischemic Stroke1-2 yearsConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteCardiologyNeurology

Placental Vascularization Study: Contrast Ultrasound

We are examining how contrast-enhanced ultrasound can help assess blood flow in the placenta for patients undergoing medical termination of pregnancy. This study compares cases of fetal growth restriction with those without to better understand placental health.

Fetal Growth RestrictionConfirmation phase (III)No PlaceboStandard MedicinesGynecology and ObstetricsInternal Medicine

Nerve Damage from Cancer: New Immunotherapy Approach

We are studying a combination of treatments for patients with anti-Hu-associated nerve damage due to cancer. The goal is to see if this early immunotherapy improves symptoms and helps patients live longer without cancer progression.

Paraneoplastic Neurological Syndrome>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesNeurologyOncology

Myeloid Malignancies: PF-08046040/SEA-CD70

We are studying the safety of a new treatment for patients with myeloid malignancies. This research aims to understand how well the treatment is tolerated by patients.

Acute Myeloid LeukaemiaMyelodysplastic Syndrome>2 yearsSafety phase (I)HematologyOncology

Bone Health: Identifying Risks from Glucocorticoids

We are studying how to find biomarkers that indicate a risk of bone disease in people taking glucocorticoids. This research may help improve monitoring and prevention strategies for affected individuals.

Secondary Osteoporosis≤3 monthsEfficacy phase (II)≤5 visitsStandard MedicinesCost ReimbursementEndocrinologyRheumatology

Coronary Artery Disease: SYN2 PET Scan Study

We are testing a new tracer for PET scans to see if it helps diagnose coronary artery disease in patients who may have it. The study will also assess the safety of this new diagnostic method.

Coronary Artery Disease>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesCardiology

Non-Hodgkin Lymphoma: IPH6501 Treatment Study

We are investigating a new drug, IPH6501, for patients with relapsed or refractory Non-Hodgkin Lymphoma. The study focuses on its safety and early signs of effectiveness in treating this type of cancer.

Refractory Non-Hodgkin's LymphomaSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

Influenza Vaccine Study for Adults Aged 65-79

We are comparing a high-dose flu vaccine to a standard-dose vaccine to see which one better reduces hospital visits for flu and pneumonia in older adults. This study aims to improve vaccine effectiveness for this age group.

Prevention of Influenza Infection in Older AdultsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious Diseases

Prostate Cancer: Pembrolizumab Combination Therapy

We are studying a new combination therapy with pembrolizumab for men with metastatic castration-resistant prostate cancer. The trial aims to evaluate its safety and how well it reduces PSA levels compared to standard treatments.

Metastatic Castration-Resistant Prostate CancerSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Alcohol Dependence: Sodium Oxybate Study

We are investigating whether Sodium Oxybate can help reduce alcohol consumption in people with high drinking risk levels. This study aims to support individuals in maintaining abstinence from alcohol.

Alcohol Addiction3-6 monthsConfirmation phase (III)6-10 visitsStandard MedicinesPsychiatry

Multiple Myeloma: TNB-383B Treatment Study

We are evaluating a new treatment for patients with multiple myeloma to see how safe it is and how well it works. This study will help us understand the maximum dose that can be tolerated.

Relapsed or Refractory Multiple Myeloma>2 yearsSafety phase (I)HematologyOncology

Bomedemstat for Blood Disorders: Safety and Efficacy Study

We are studying the safety of bomedemstat for individuals with essential thrombocythemia, polycythemia vera, or myelofibrosis who participated in a previous study. The trial also examines how well the treatment manages these conditions over time.

Myeloproliferative Neoplasms>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyOncology

Glioblastoma Treatment: Lomustine and Temozolomide Study

We are studying whether a combination of lomustine and temozolomide improves survival for newly diagnosed glioblastoma patients with a specific genetic marker. This trial also looks at side effects and quality of life compared to standard treatment.

Glioblastoma6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesNeurologyOncology

Gene Therapy for Crigler-Najjar Syndrome: GNT0003

We are studying a new gene therapy to see if it is safe and effective for patients with severe Crigler-Najjar syndrome who need phototherapy. This trial will help us understand how it may improve their health and quality of life.

Crigler-Najjar Syndrome>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesPartially RemoteHepatology

Triple-Negative Breast Cancer: Keytruda with Chemotherapy

We are studying how different chemotherapy regimens combined with Keytruda affect the immune response in patients with early-stage triple-negative breast cancer. The goal is to find the most effective treatment approach for this specific cancer type.

Triple Negative Breast Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Coronary Artery Disease: Angiolite Stent and Antiplatelet Therapy Study

We are evaluating whether a new stent and a shorter antiplatelet therapy can reduce complications in patients with coronary artery disease. This study compares these approaches to standard treatment options.

Coronary Artery Disease>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteCardiology

Primary Cold Agglutinin Disease: ANX1502 Treatment Study

We are assessing a new treatment, ANX1502, for individuals with Primary Cold Agglutinin Disease. This study aims to understand its safety and how it affects the condition.

Cold Agglutinin Disease1-2 yearsSafety phase (I)HematologyInternal Medicine

Ovarian Stimulation in Older Women: INOVEE Study

We are comparing two doses of a fertility medication to see which produces more healthy embryos in older women undergoing fertility treatment. This study aims to improve outcomes for women trying to conceive.

Female Infertility3-6 monthsMonitoring phase (IV)No PlaceboStandard MedicinesEndocrinologyGynecology and Obstetrics

Dilated Cardiomyopathy: Candesartan vs Placebo

We are studying whether early treatment with candesartan can help prevent heart function decline in people with a genetic risk for dilated cardiomyopathy who currently have no symptoms. The trial also looks at the safety of this medication.

Dilated Cardiomyopathy>2 yearsConfirmation phase (III)11-15 visitsStandard MedicinesPartially RemoteCardiologyInternal Medicine